论文部分内容阅读
目的观察替普瑞酮联合法莫替丁治疗非萎缩性胃炎的临床效果。方法 110例非萎缩性胃炎患者,随机分为观察组和对照组,每组55例,对照组患者采用法莫替丁进行治疗,观察组患者在对照组治疗的基础上联合应用替普瑞酮进行治疗。比较两组患者的治疗有效率、临床症状积分以及不良反应发生情况。结果观察组患者的总有效率94.55%,显著高于对照组患者的80.00%,差异有统计学意义(P<0.05);观察组治疗后临床症状积分显著优于对照组,差异有统计学意义(P<0.05);观察组患者的不良反应发生率为9.09%(5例),与对照组患者的7.27%(4例)比较,差异无统计学意义(P>0.05)。结论替普瑞酮联合法莫替丁治疗非萎缩性胃炎可以明显的减轻患者的临床症状,取得比较满意的治疗效果,值得广泛推广。
Objective To observe the clinical effect of teprenone plus famotidine in the treatment of non-atrophic gastritis. Methods A total of 110 patients with non-atrophic gastritis were randomly divided into observation group and control group, 55 cases in each group. The patients in the control group were treated with famotidine. The patients in the observation group were treated with teprenone For treatment. The treatment efficiency, clinical symptom scores and adverse reactions of the two groups were compared. Results The total effective rate in the observation group was 94.55%, which was significantly higher than that in the control group (80.00%), the difference was statistically significant (P <0.05); the clinical symptom scores in the observation group were significantly better than those in the control group (P <0.05). The incidence of adverse reactions in the observation group was 9.09% (5 cases), and there was no significant difference between the observation group and the control group (7.27%, 4 cases) (P> 0.05). Conclusion Teprenone combined with famotidine in the treatment of non-atrophic gastritis can significantly reduce the clinical symptoms of patients and obtain more satisfactory treatment, it is worth widely disseminated.